No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Barclays Reaffirms Their Hold Rating on Blueprint Medicines (BPMC)
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Stifel Nicolaus Sticks to Its Buy Rating for Blueprint Medicines (BPMC)
J.P. Morgan Maintains Blueprint Medicines(BPMC.US) With Buy Rating
Those Who Invested in Blueprint Medicines (NASDAQ:BPMC) Five Years Ago Are up 17%
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer